Meeting Agenda
Integrating Neuroscience, Developmental Psychopathology, and Preventive Interventions: Critical Questions for the Next Generation of Transformative Research
June 01, 2010
Denver, Colorado
| Time | Event |
|---|
| 8:30 a.m. | Arrival and Refreshments |
| 9:00 a.m. | Welcome, Overview of Meeting Goals Christopher Gordon, PhD
Welcome and Introduction Amy Goldstein, PhD
Overview of Meeting Goals |
| 9:15 a.m. | Session 1: Biological Targets in Prevention Trials: What are Appropriate Targets and How Should They be Assessed? - Presentations
- Raquel Gur, MD, PhD
Implications of genetics for prevention research - Catherine Monk, PhD
Possible biomarkers for intervention studies: Blood, sweat, and hair - Damien Fair, PhD
Studying the brain at rest: Using functional connectivity MRI to examine typical and atypical development - Discussants
- David Olds, PhD
- Joan Luby, MD
- Moderator
- Christopher Gordon, PhD
|
| 11:15 a.m. | Session 2: Designing Prevention Trials with a Neurodevelopmental Perspective - Presentations
- Martin Teicher, MD
Sensitive and silent periods in neurodevelopment for emergence of psychopathology - Barbara Cornblatt, MD
Prevention of mental illnesses - Mary Dozier, PhD
Integration of behavioral and biomarkers for risk in prevention trials - Discussants
- Irwin Sandler, PhD
- Patrick Tolan, PhD
- Moderator
- Amy Goldstein, PhD
|
| 2:15 p.m. | Session 3: Implications of the Next Generation of Prevention Research for Communities at Risk - Presentations
- Holly Moore, PhD
Perspectives in prevention research: The role of preclinical neuroscience research - Manpreet Singh, MD
Risk and protective factors for bipolar disorder: Can we reduce morbidities and promote resilience? - Rachel Yehuda, MD
Acceptability of early pharmacological intervention for PTSD - Discussants
- John Mann, MD
- Ron Prinz, PhD
- Moderator
- Christopher Sarampote, PhD
|
| 4:00 p.m. | Next Steps |
